Application Serial No. 09/674,752

Filing Date: December 29, 2000.

Docket: 294-86 PCT/US/RCE II

Page 2 of 6

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listing of claims in the application.

Claims 1-86: (Cancelled).

87. (Currently Amended) An isolated <u>antibody or fragment thereof polypeptide</u> capable of specific binding to factor VIII and comprising a heavy chain variable region of a human antibody with factor VIII specificity and a light chain variable region of a human antibody, wherein the heavy chain variable region comprises a sequence selected from the group consisting of SEQ. ID. NO: 23, SEQ. ID. NO: 25, SEQ. ID. NO: 27, SEQ. ID. NO: 32, SEQ. ID. NO: 34, SEQ. ID. NO: 36, SEQ. ID. NO: 38, SEQ. ID. NO: 49, and SEQ. ID. NO: 51.

88. (Cancelled).

89. (Currently Amended) The isolated <u>antibody or fragment thereof polypeptide</u> of claim 87, which is capable of interfering with the activity of factor VIII inhibitors, and wherein the heavy chain variable region comprises a sequence selected from the group consisting of SEQ. ID. NO: 25, <u>and SEQ. ID. NO: 27</u>, and <u>SEQ. ID. NO: 28</u>.

90. (Currently Amended) The isolated <u>antibody or fragment thereof polypeptide</u> of claim 87, wherein the heavy chain variable region comprises a sequence selected from the group consisting of SEQ. ID. NO: 32, SEQ. ID. NO: 34, SEQ. ID. NO: 36, SEQ. ID. NO: 38, SEQ. ID. NO: 49 and SEQ. ID. NO: 51.

91. (Currently Amended) The isolated <u>antibody or fragment thereof polypeptide</u> of claim 87, wherein said polypeptide is a single chain Fv fragment.

Application Serial No. 09/674,752

Filing Date: December 29, 2000.

Docket: 294-86 PCT/US/RCE II

Page 3 of 6

92. (Currently Amended) The isolated <u>antibody or fragment thereof polypeptide</u> of claim 87, wherein said polypeptide is an antibody.

- 93. (Currently Amended) The isolated <u>antibody or fragment thereof polypeptide</u> of claim 92, wherein said antibody is an IgG.
- 94. (Currently Amended) The isolated <u>antibody or fragment thereof polypeptide</u> of claim 87, wherein said polypeptide specifically binds the heavy chain of factor VIII.
- 95. (Currently Amended) The isolated <u>antibody or fragment thereof polypeptide</u> of claim 87, wherein said polypeptide specifically binds a domain of the heavy chain of factor VIII consisting of the A1 domain, the A2 domain and the B domain of factor VIII.
- 96. (Currently Amended) The isolated <u>antibody or fragment thereof polypeptide</u> of claim 87, wherein said polypeptide specifically binds the light chain of factor VIII.
- 97. (Currently Amended) The isolated <u>antibody or fragment thereof polypeptide</u> of claim 87, wherein said polypeptide specifically binds a region of the light chain of factor VIII consisting of the A3 domain, the C1 domain and the C2 domain of factor VIII.
- 98. Currently Amended) A composition for the treatment of factor VIII inhibition in a human individual, comprising the isolated antibody or fragment thereof polypeptide according to claim 87 together with a pharmaceutically acceptable carrier.
- 99. (Currently Amended) A composition for the treatment of factor VIII inhibition in a human individual, comprising the isolated antibody or fragment thereof polypeptide according to claim 90 together with a pharmaceutically acceptable carrier.

Application Serial No. 09/674,752 Filing Date: December 29, 2000. Docket: 294-86 PCT/US/RCE II

Page 4 of 6

100. (Currently Amended) A composition for the treatment of factor VIII inhibition in a human individual, comprising the isolated antibody or fragment thereof polypeptide according to claim 89 together with a pharmaceutically acceptable carrier.